Core Viewpoint - The demand for Chinese graduates in Malaysia is expected to grow significantly due to the increasing presence of Chinese companies, particularly in manufacturing and technology sectors, creating lucrative job opportunities for local and foreign talent [5][10][26]. Group 1: Job Market Dynamics - Chinese graduates, especially those with degrees from Malaysian universities, are becoming highly sought after in the job market, with salaries significantly higher than local averages [10][17]. - The average starting salary for local graduates is around 3,079 MYR (approximately 5,423 RMB), while Chinese graduates are receiving offers around 6,000 MYR (approximately 10,568 RMB), which is double the local average [9][10]. - The job market is experiencing structural changes, with a growing need for individuals who can bridge the cultural and operational gaps between Chinese companies and the local workforce [14][19]. Group 2: Industry Growth and Investment - In 2024, the bilateral trade between China and Malaysia reached 212.04 billion USD, marking an 11.4% year-on-year increase, solidifying China's position as Malaysia's largest trading partner [13]. - Chinese companies are expanding their operations in Malaysia, with significant investments in sectors such as electric vehicles, smart manufacturing, and renewable energy [15]. - The manufacturing sector is projected to see a demand growth rate of 20%-30% annually from 2024 to 2025, driven by the influx of Chinese enterprises [14][26]. Group 3: Cultural and Operational Challenges - There is a noticeable disparity in salaries between Chinese and local employees, leading to tensions in the workplace, as local employees perceive the high salaries of Chinese counterparts as unfair [17][19]. - The cultural differences and varying work ethics between local and Chinese employees pose challenges for integration and productivity within companies [19][26]. - Chinese companies are adapting their hiring strategies, increasingly favoring local talent to reduce costs and improve operational efficiency, while also recognizing the need for bilingual employees who understand both local culture and Chinese corporate practices [14][19]. Group 4: Future Outlook - The trend of high salaries and job opportunities for Chinese graduates in Malaysia may not be sustainable in the long term, as companies may shift towards local hiring to cut costs [23][26]. - The expansion of Chinese companies in Malaysia reflects a structural change rather than a speculative bubble, although challenges such as competition with local firms and labor market pressures remain [26][27]. - The future of Chinese graduates in Malaysia will depend on their ability to adapt to local conditions and the evolving needs of the job market, with potential for both opportunities and challenges ahead [26][27].

Core Viewpoint - The company, Lianhua Technology, anticipates stable operational performance at its UK base in 2025 and expects to maintain steady growth in 2026 [1] Group 1: Investment Plans - The company plans to invest $200 million in its Malaysia base, which is currently in the first phase of construction [1] - The first phase of the Malaysia project is expected to be completed by the end of 2026, with production commencing in 2027 based on customer orders [1] Group 2: Product and Service Offerings - The Malaysia base is primarily planned for the production of agricultural CDMO products [1] - The company aims to provide a full supply chain service to customers from China, the UK, and Malaysia, catering to different product lifecycle needs [1] - The strategy leverages China's comprehensive chemical supply chain and competitive resources, along with the flexible production and registration policies in the UK and Malaysia [1]

Group 1: New Energy Business - The company primarily focuses on the sales of LiFSI, cathode materials, and electrolyte products, with ongoing technical improvements on lithium hexafluorophosphate projects. Revenue from the new energy business is expected to break through in 2025, with further growth anticipated in 2026 [1] - The company aims to expand its product range and market presence in the new energy sector, leveraging its R&D and production capabilities to convert technological advantages into market benefits [1] - The new energy sector is viewed as a sufficiently broad and long-term opportunity, helping to mitigate operational risks associated with the company's previous focus on overseas CDMO clients [2] Group 2: Overseas Operations - The UK base has maintained stable production and operations in 2025, with expectations for continued stability in 2026. The Malaysian base plans to invest $200 million, with the first phase of construction ongoing and expected to complete by the end of 2026 [3] - The Malaysian facility will focus on producing agricultural CDMO products, with plans to gradually commence production based on customer orders starting in 2027 [3] Group 3: Pharmaceutical Business - The pharmaceutical segment has shown steady growth, with a focus on a large client strategy and CDMO business model. The company has established stable commercial relationships with several leading global pharmaceutical companies [4] - The company is actively expanding its client base and developing new strategic partnerships, particularly with high-viscosity clients, while also focusing on small molecule CDMO and emerging business areas such as peptide products and radiopharmaceuticals [4] Group 4: Client Dependency and Market Strategy - The company acknowledges a high concentration of clients but emphasizes the importance of providing comprehensive services to existing clients while actively seeking new customers across various sectors [4] - The strategy includes enhancing technical capabilities and market expansion to foster long-term cooperation and mutual trust with clients, ensuring a sustainable business model [4]

Group 1: Company Overview - Company held a specific investor meeting on January 5, 2026, in Shanghai, attended by nine institutions including Tianfeng Securities and Southern Fund [1][2] - Senior Vice President and Secretary of the Board, Chen Feibiao, along with Securities Affairs Representative Dai Yiyi, discussed key issues such as the progress in the new energy business, overseas base layout, and pharmaceutical business planning [1][2] Group 2: New Energy Business - The new energy business is focused on the sales of LiFSI and electrolyte products, with a breakthrough in revenue achieved in 2025 and expected continued growth in 2026 [2] - The lithium hexafluorophosphate project is currently in the technical improvement stage, with ongoing optimization of product competitiveness through systematic process development [2] - The company leverages its long-standing experience in chemical synthesis to enhance its market position in the new energy sector [2] Group 3: Overseas Operations - The UK production base is operating smoothly in 2026, while the Malaysian base is under phased construction, primarily aimed at producing agricultural CDMO products [3] - The company plans to integrate resources from China, the UK, and Malaysia to provide comprehensive supply chain solutions covering the entire product lifecycle [3] Group 4: Pharmaceutical Business - The pharmaceutical business focuses on a CDMO model and has established partnerships with several leading global pharmaceutical companies, while also expanding its client base [4] - The business primarily serves products under patent, with long-term growth expected as these products are promoted [4] - Future development will emphasize small molecule CDMO, starting materials, and registration materials, while also investing in emerging areas such as peptides and radiopharmaceuticals [4] Group 5: Risk Management - The company acknowledges potential revenue impacts from the expiration of patents for agricultural clients but plans to mitigate this through product and technology upgrades [6]

Group 1: New Energy Business - The company primarily focuses on the sales of LiFSI and electrolyte products, while also improving the lithium hexafluorophosphate project through systematic process development [1] - In 2025, the company's new energy business revenue is expected to achieve a breakthrough, with continuous expansion of product varieties and market opportunities [1] - The revenue and profit performance of the new energy business is anticipated to further improve [1] Group 2: Strategic Entry into New Energy Sector - The company has been engaged in the chemical field since its establishment, with a focus on chemical synthesis, which includes new energy-related chemicals [1] - The new energy sector is viewed as a sufficiently broad and long-term opportunity, allowing the company to hedge operational risks associated with its primary CDMO business for overseas clients [1] Group 3: Overseas Operations - The UK base has maintained stable production and operational conditions this year, while the Malaysian base is under phased construction, primarily focusing on producing CDMO products for plant protection [3] - The company aims to provide a full supply chain service from China, the UK, and Malaysia, leveraging competitive resources and flexible production policies [3] Group 4: Pharmaceutical Business - The pharmaceutical business adopts a major client strategy, primarily through the CDMO model, and has established stable commercial relationships with several leading global pharmaceutical companies [4] - The company plans to expand its mature business areas, including small molecule CDMO and GMP intermediates, while also investing in emerging business developments such as peptide CDMO and radioactive drug CDMO [4] Group 5: Impact of Patent Expiry - Some plant protection clients are facing patent expirations, but the overall impact on the company is expected to be limited [5] - The company can continue to upgrade products and technologies with relatively low capital expenditure compared to new capacity investments, allowing it to maintain stable revenue despite natural declines from patent expirations [6]